Pharmacological interaction of lopinavir/ritonavir 800/200 mg BID and rifampicin in subjects presenting tuberculosis with contraindication for an efavirenz containing antiretroviral regimen.

@inproceedings{Schmaltz2014PharmacologicalIO,
  title={Pharmacological interaction of lopinavir/ritonavir 800/200 mg BID and rifampicin in subjects presenting tuberculosis with contraindication for an efavirenz containing antiretroviral regimen.},
  author={Carolina Arana Stanis Schmaltz and Marli Jane Marins Costa and Vit{\'o}ria Berg Cattani and Douglas Pereira Pinto and Jos{\'e} Liporage and Aline Benjamin and Catherine N. Boulanger and Mariza Gonçalvez Morgado and Valeria C Rolla},
  year={2014}
}
Rifampicin reduces plasma concentration of most HIV protease inhibitors. Lopinavir boosted with ritonavir (LPV/r) could be an option to treat TB-HIV patients. Our aim was to evaluate lopinavir interaction with rifampicin during TB-HIV therapy. TB-HIV patients who could not use efavirenz and with no genotypic resistance to lopinavir were included. Rifampicin 600 mg, isoniazid 400 mg and pyrazinamide 2000 mg were started at day one for 6 months and LPV/r plus two nucleoside/nucleotide reverse… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…